ETBX 011

Drug Profile

ETBX 011

Alternative Names: Ad5 [E1-, E2B-]-CEA(6D); AD5 CEA vaccine; Ad5[E1-,E2b-]-CEA vaccine; CEA-targeted vaccine - Etubics; ETBX-011

Latest Information Update: 29 Sep 2015

Price : $50

At a glance

  • Originator Etubics Corporation
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 29 Sep 2015 Clinical development is ongoing in the USA
  • 23 Jun 2015 Etubics establishes CRADA with National Cancer Institute for the development of immunotherapeutic product candidates in cancer
  • 28 May 2014 Adverse events and efficacy data from a phase I/II trial in Solid tumours released by Etubics Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top